> Details

Briest, Franziska; Grass, Irina; Sedding, Dagmar; Möbs, Markus; Christen, Friederike; Benecke, Joana; Fuchs, Karolin; Mende, Stefanie; Kaemmerer, Daniel; Sänger, Jörg; Kunze, Almut; Geisler, Christina; Freitag, Helma; Lewens, Florentine; Worpenberg, Lina; Iwaszkiewicz, Sara; Siegmund, Britta; Walther, Wolfgang; Hummel, Michael; Grabowski, Patricia

Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors
  • Contributor: Briest, Franziska; Grass, Irina; Sedding, Dagmar; Möbs, Markus; Christen, Friederike; Benecke, Joana; Fuchs, Karolin; Mende, Stefanie; Kaemmerer, Daniel; Sänger, Jörg; Kunze, Almut; Geisler, Christina; Freitag, Helma; Lewens, Florentine; Worpenberg, Lina; Iwaszkiewicz, Sara; Siegmund, Britta; Walther, Wolfgang; Hummel, Michael; Grabowski, Patricia
  • Published: S. Karger AG, 2018
  • Published in: Neuroendocrinology, 107 (2018) 1, Seite 1-23
  • Language: English
  • DOI: 10.1159/000481506
  • ISSN: 0028-3835; 1423-0194
  • Origination:
  • Footnote:
  • Description: <b><i>Background/Aims:</i></b> The tumor suppressor p53 is rarely mutated in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) but they frequently show a strong expression of negative regulators of p53, rendering these tumors excellent targets for a p53 recovery therapy. Therefore, we analyzed the mechanisms of a p53 recovery therapy on intestinal neuroendocrine tumors in vitro and in vivo<i>.</i><b><i>Methods:</i></b> By Western blot and immunohistochemistry, we found that in GEP-NEN biopsy material overexpression of MDM2 was present in intestinal NEN. Therefore, we analyzed the effect of a small-molecule inhibitor, nutlin-3a, in p53 wild-type and mutant GEP-NEN cell lines by proliferation assay, flow cytometry, immunofluorescence, Western blot, and by multiplex gene expression analysis. Finally, we analyzed the antitumor effect of nutlin-3a in a xenograft mouse model in vivo. During the study, the tumor volume was determined. <b><i>Results:</i></b> The midgut wild-type cell line KRJ-I responded to the treatment with cell cycle arrest and apoptosis. By gene expression analysis, we could demonstrate that nutlins reactivated an antiproliferative p53 response. KRJ-I-derived xenograft tumors showed a significantly decreased tumor growth upon treatment with nutlin-3a in vivo. Furthermore, our data suggest that MDM2 also influences the expression of the oncogene FOXM1 in a p53-independent manner. Subsequently, a combined treatment of nutlin-3a and cisplatin (as chemoresistance model) resulted in synergistically enhanced antiproliferative effects. <b><i>Conclusion:</i></b> In summary, MDM2 overexpression is a frequent event in p53 wild-type intestinal neuroendocrine neoplasms and therefore recovery of a p53 response might be a novel personalized treatment approach in these tumors.